Co-encapsulation of hepatocytes, mesenchymal stem cells and growth factor in arginine-glycine-aspartate functionalized microbeads for liver disease
1
Issued Date
2025-01-01
Resource Type
ISSN
20563418
eISSN
20563426
Scopus ID
2-s2.0-105017743965
Journal Title
Regenerative Biomaterials
Volume
12
Rights Holder(s)
SCOPUS
Bibliographic Citation
Regenerative Biomaterials Vol.12 (2025)
Suggested Citation
Win S.Y., Nittayacharn P., Saingam A., Sa-Ngiamsuntorn K., Nasongkla N. Co-encapsulation of hepatocytes, mesenchymal stem cells and growth factor in arginine-glycine-aspartate functionalized microbeads for liver disease. Regenerative Biomaterials Vol.12 (2025). doi:10.1093/rb/rbaf094 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/112536
Title
Co-encapsulation of hepatocytes, mesenchymal stem cells and growth factor in arginine-glycine-aspartate functionalized microbeads for liver disease
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Acute liver failure is a life-threatening condition with limited treatment options, primarily liver transplantation, which is constrained by donor shortages and lifelong immunosuppression. This study presents a minimally invasive therapeutic approach using multifunctional microbeads co-encapsulating two cell types: immortalized hepatocytes and umbilical cord-derived mesenchymal stem cells, along with basic fibroblast growth factor-loaded poly(lactide-co-glycolide) microspheres. The alginate microbeads are functionalized with poly(ethylene glycol) and the arginine-glycine-aspartate tripeptide to enhance cell adhesion and are crosslinked via click chemistry for improved structural integrity. The bFGF-loaded PLGA microspheres were synthesized using a double-emulsion solvent evaporation method, achieving an average size of 4.25±2.20µm, a loading content of 0.078% and an entrapment efficiency of 3.52±0.27%. Sustained bFGF release over 14days (cumulative 2.39±0.20ng) enhanced hepatocyte proliferation, human mesenchymal stem cell differentiation and cell viability. Functional assessment demonstrated significantly improved hepatocyte performance, with microbeads producing 2032.53±29.45ng of albumin and 1057.00±9.19ng of alpha-fetoprotein over 14days. Overall, this co-encapsulation strategy enhances hepatocyte regeneration, viability, function and offers a scalable therapeutic platform for ALF. Future studies should optimize the formulation and evaluate long-term efficacy in vivo.